Increased plasma fibrinopeptide a levels during attacks induced by hyperventilation in patients with coronary vasospastic angina  by Oshima, Shuichi et al.
1
50
Increased Plasma Fibrinopeptide A Levels During Attacks Induced by
Hyperventilation in Patients With Coronary Vasospastic Angina
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KOSHI MATSUYAMA, MD, HIROO MIYAGI, MD
Kumamoto, Japan
Plasma fibrinopeptide A levels, beta-thromboglobulin levels
and platelet factor 4 levels were estimated by enzyme-linked
immunosorbent assay before and after hyperventilation in
12 patients with coronary vasospastic angina and in 12
control subjects matched for age and gender . In all 12 study
patients, anginal attacks accompanied by electrocardio-
graphic (ECG) changes (ST elevation in 11 patients and ST
depression in 1 patient) were induced by hyperventilation .
Coronary angiography was performed on 11 of the 12
patients, and coronary artery spasm with the same ECG
changes was induced by intracoronary injection of acetyl-
choline in all 11 .
Intracoronary thrombus formation has been thought to play
an important role in the genesis of acute myocardial infarc-
tion (1,2) and unstable angina (3,4) . The presence of coro-
nary thrombus implies that the coagulation mechanism has
been activated and thrombin has been generated to convert
fibrinogen to fibrin . Fibrinopeptide A is a very sensitive and
specific marker of thrombin generation in vivo and of acti-
vation of the coagulation system (5) . Several investigators
(6-10) have studied fibrinopeptide A and platelet proteins in
acute myocardial infarction and unstable angina, and have
suggested that these pathologic processes are associated
with activation of the hemostatic system . On the other hand,
whether coronary artery spasm can trigger the thrombotic
process in the coronary artery is an important and unre-
solved issue . Several investigators (11-14) have reported
that coronary artery spasm is a cause of myocardial infarc-
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The plasma fibrinopeptide A levels increased signifi-
cantly from 2 .0 ± 0 .4 to 10.0 ± 2 .4 ng/ml during the attack
(p < 0 .001) in the study patients, but remained unchanged
before and after hyperventilation in the control subjects .
The plasma levels of beta-thromboglobulin and platelet
factor 4 remained unchanged after hyperventilation in both
groups .
Our data indicate that coronary artery spasm may
induce thrombin generation and trigger thrombus forma-
tion in the coronary artery .
(.1 Am Coll Cardiol 1 8  ;14 150-4)
tion in some patients ; however, direct cause and effect have
not been shown in most cases .
The purpose of this study was to determine whether
coronary artery spasm causes thrombin generation or plate-
let activation, or both . We examined the activation of the
hemostatic system before and after coronary artery spasm
induced by hyperventilation, which has been shown to
provoke coronary artery spasm in patients with variant
angina (15) . Fibrinopeptide A was used as an index of
thrombin generation, and beta-thromboglobulin and platelet
factor 4 were used to detect in vivo platelet activation .
Methods
Study patients
. Twelve consecutive patients with coro-
nary vasospastic angina, in whom an anginal attack could be
induced by hyperventilation, were studied . Coronary vaso-
spastic angina was diagnosed when one of the following
criteria was fulfilled   1) angina at rest, with ST segment
elevation (variant angina), or 2) spasm of a major coronary
artery supplying the area of myocardium represented by ST
segment elevation or depression on the electrocardiogram
(ECG) and demonstrated during the anginal attack by coro-
nary arteriography . All patients with coronary vasospastic
angina had recurring attacks of chest pain at rest in associ-
ation with ST segment elevation or depression . Their age,
0735-10 7/8 /$3
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Table 1 . Electrocardiographic and Coronary Arteriographic
Findings in 12 Patients With Vasospastic Angina
Coronary Arteriogram
I% stenosis)
Age
Patient
	
(yr)/ ECG Changes During
No . Gender Attack Attack After NTG
1 57/M ST T in I1,I11,aVF    S 7 N
67/M ST T in 11 .111,aVF - -
3 48/M ST T in V, ,,, , 100 S7 N
4 60/M ST T in 11,I11,aVF 100 S,
 0s,
5 56/M ST T in 11,I11,aVF 100s, N
6 45/M
ST
T
in 1I,111,aVF 100s, N
7 56/M
ST
T in 11,111,aVF, or
  s,
N
ST T in V, 100 S 1,
8
63/F
ST J in V, ,,, ,
   S„ N
  72/M ST
T
in I1,111,aVF 100s, N
10 6 /M ST
T
in 11 .111,aVF 100s, N
I I 61/M
ST
T in V,, ,,,
  s,
N
12 53/M ST
T
in ILII1 .aVF or 100 S, N
ST T in I,aVL .V,,,, , 100 S fi
ECG =- electrocardiographic ; F = female   M = male   N = normal or
<25% stenosis   NTG = nitroglycerin   ST T or ST
1
= ST segment elevation
or depression, respectively   S, to S
8 refers to the segment of the coronary
arteries as defined by the American Heart Association Committee Report
Circulation 1 75  51(41  5-40 .
gender, ECG changes during the attack and coronary angio-
graphic findings are shown in Table 1 . Patients with prior
myocardial infarction, and those receiving heparin .
coumarin anticoagulant and antiplatelet agents were ex-
cluded from the study . Patients with thromboembolism, a
prosthetic heart valve or a pacemaker were also excluded .
Administration of all medications, except nitroglycerin, was
stopped at least 3 days before the study .
Twelve patients (I 1 men and I woman) whose age ranged
from 44 to 67 years (mean 55 .5) were matched for age and
gender with the patients with coronary vasospastic angina
and were selected as control subjects . The control group
comprised seven patients with atypical chest pain, three with
stable exertional angina, one with hypertensive heart disease
and one with congenital heart disease . Written informed
consent was obtained from each patient and the study
protocol was approved by the Kumamoto University Medi-
cal School Ethics Committee .
Study protocol . After blood pressure and 12 lead ECG
were recorded and control blood samples for fibrinopeptide
A, beta-thromboglobulin and platelet factor 4 and arterial
blood for pH and gas analysis were obtained, the patients
performed hyperventilation for 6 min, during constant mon-
itoring of blood pressure and the ECG . Hyperventilation was
stopped immediately when chest pain or ischemic changes
on the ECG occurred . Blood samples for fibrinopeptide A,
beta-thromboglobulin and platelet factor 4 were taken again
during chest pain and ECG ischemic changes, at about 2 min
after the onset of the ECG changes, in the patients with
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coronary vasospastic angina and at the end of hyperventila-
tion in the control subjects. Arterial blood for pH and gas
analysis was taken again at the end of hyperventilation in
both groups. All studies were performed between 7  00 AM
and   00 AM because coronary spasm is easily induced in the
early morning (15) . Coronary arteriography was performed
on I I of the 12 patients with coronary vasospastic angina and
on all the control subjects within I week of the hyperventi-
lation test .
Blood samples and assay. Blood was obtained from a
clean venipuncture of an antecubital vein without stasis by
the two-syringe method with a 21 gauge needle (5,16) . The
initial 3 ml of blood was discarded and the subsequent
sample was collected in a sequential manner directly into
syringes containing the appropriate anticoagulant mixtures
and processed immediately . The anticoagulant mixtures for
fibrinopeptide A consisted of aprotinin, 1,000 Kallidinoge-
nase Inaktivator Einheiten (KIE)/ml ; heparin, 1,000 U/ml
and sodium citrate, 0.11 M; those for beta-thromboglobulin
and platelet factor 4 consisted of theophilline, 15 mM,
adenosine. 3 .7 mM  dipyridamole, 0.1 8 mM and sodium
citrate, 0 .11 M . They were provided by Diagnostica Stago,
Inc., France . The quality of the sampling procedure was
critically noted prospectively, and inappropriate samples
were discarded . Samples were judged to be inappropriate if
the venipuncture was faulty and the blood did not flow
freely . In this study, one sample for fibrinopeptide A and two
samples for beta-thromboglobulin and platelet factor 4 were
discarded. The mixtures of samples for fibrinopeptide A and
anticoagulants were promptly centrifuged at 3,000 g for 10
min at 4°C. Samples for beta-thromboglobulin, platelet fac-
tor 4 and anticoagulants were placed in melting ice for > 15
min, then centrifuged at 3,000 g for 30 min at 4 °C . Each
supernatant plasma was stored frozen at -80°C until as-
sayed. The assay was performed within I month .
Fibrinope ptide A, beta-thromboglobulin and platelet fac-
tor4levels were measured by the commercial enzyme-linked
immunosorbent assay kits produced by Diagnostica Stago
Inc. (16-18) . Fibrinopeptide A levels were measured in
plasma samples, from which fibrinogen was completely
removed by adsorption with bentonite, according to the
method of Kockum and Frebelius (1 ), using bentonite
supplied as a kit . The respective variabilities of intra- and
interassay for fibrinopeptide A (n = 20) were 5 .7% and  .2%,
those for beta-thromboglobulin (n = 12) were 2.8% and 8 .1 %
and those for platelet factor 4 (n = 12) were 4 .5% and 6.7% .
The normal mean values (+ SE) for fibrinopeptide A,
beta-thromboglobulin and platelet factor 4 in our laboratory
were 1 .6 ± 0 .1 ng/ml, 22 .8 ± 1 .01U/ml and .3.4 ± 0 .2 IU/mi,
respectively . The blood samples were measured in dupli-
cate .
The enzyme-linked immunosorbent assay methods used
in this study were developed by Amiral and coworkers
(16-18) and have been shown to be specific, sensitive,
152
	
OSHIMA ET AL .
FIBRINOPEPTIDE A IN VASOSPASTIC ANGINA
Before HV
After HV
(Attack)
Figure 1 . Patient 6. Electrocardiogram, plasma fibrinopeptide A
(FPA) levels, blood pressure (BP) and arterial pH and partial
pressure of carbon dioxide (Pco,) before (left panel) and after (right
panel) hyperventilation (HV)
. ST segment elevation in leads II . III
and aVF associated with chest pain appeared and plasma FPA levels
increased after hyperventilation .
reproducible and satisfactory for routine clinical application .
These methods are comparable with those of commercially
available radioimmunoassay kits for both clinical and normal
samples .
Statistical analysis . Fibrinopeptide A, beta-thromboglob-
ulin and platelet factor 4 levels for each patient are expressed
as mean value ± SEM . Because the measured levels of these
factors show a marked skewness toward high values (20,21),
logarithmic transformation was required to obtain normal
distributed variables . Statistical analyses were performed by
Student's t test for paired variables . Probability levels were
considered to be statistically significant at <0 .05 .
Results
Findings during hyperventilation test. Most patients ex-
perienced mild light-headedness and numbness of hands,
feet and lips, which began after 2 to 3 min and continued
throughout the period of hyperventilation . In all 12 patients
with coronary vasospastic angina, chest pain with ischemic
changes on the ECG (ST segment elevation in 11 patients
and ST segment depression in I patient) was induced by
hyperventilation . In Patient 2, hyperventilation was stopped
because the anginal attack appeared 3 min after the begin-
ning of hyperventilation . In the other I 1 patients, the attack
occurred <5 min after hyperventilation was stopped . No
anginal attack with ST segment changes was induced in any
control subject .
Figure 1 shows a representative case (Patient 6) . The
anginal attack associated with ST segment elevation in leads
II, III and aVF appeared immediately after hyperventilation
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10
6
2
0
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Before HV After HV
CSA Patients
(n=12)
Figure 2. Plasma fibrinopeptide A (FPA) levels before and after
hyperventilation (HV) in the 12 control subjects (left panel) and the
12 study patients with coronary vasospastic angina (CSA) (right
panel)
. The plasma fibrinopeptide A levels in the study patients
increased significantly during the attack, but remained unchanged in
the control subjects .
was stopped. The plasma fibrinopeptide A levels increased
from 1 .7 to 8.4 ng/ml, arterial blood pH increased from 7 .40
to 7 .60 and partial pressure of carbon dioxide (Pco2) de-
creased from 42 .5 to 22 .1 mm Hg after hyperventilation .
Coronary arteriography . This was performed on 11 of the
12 patients with coronary vasospastic angina . Coronary
spasm with the same ECG changes as in the hyperventilation
test was induced by intracoronary injection of acetylcholine
(22) in all I I patients (Table 1), but in none of the 12 control
subjects .
Plasma fibrinopeptide A levels before and after hyperven-
tilation (Fig . 2, Table 2) . The plasma fibrinopeptide A levels
(ng/ml) increased significantly after the attack induced by
hyperventilation from 2 .0 ± 0 .4 to 10 .0 ± 2 .4 in the patients
with coronary vasospastic angina (p < 0 .001), but remained
unchanged in the control subjects (2 .4 ± 0 .5 to 2 .3 ± 0 .5) .
Sublingual administration of 0 .3 mg nitroglycerin was per-
formed after blood samplings during the attack in 11 of the 12
study patients ; in addition, I or 2 .5 mg nitroglycerin was
injected intravenously in 3 (Patients 2, 7 and  ) of these 11
patients because angina did not disappear after sublingual
nitroglycerin . The levels of fibrinopeptide A were greatly
elevated (11 . , 33 and 16 ng/ml, respectively) in these three
patients . On the other hand, the angina resolved spontane-
ously in one patient (Patient 8) . Additional samples for
fibrinopeptide A were obtained 15 min after the resolution of
the attack in 4 of the 12 patients ; the levels of fibrinopeptide
A decreased significantly after the resolution of the attack,
but were still higher than the levels before hyperventilation .
Three of the 12 control subjects had stable exertional angina
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Table 2 . Fibrinopeptide A, Beta-Thromboglobulin Platelet
Factor 4 (PF4) and Arterial Gas Data in Control Subjects and
Study Patients
*p < 0 .01 versus before hyperventilation   tp < 0.001 versus before
hyperventilation . Data are expressed as mean values ± SEM   BTG =
beta-thromboglobulin ; CSA = coronary vasospastic angina   FPA = fibrin-
opeptide A   HV = hyperventilation   Pco, = partial pressure of carbon
dioxide   PF4 = platelet factor 4 .
with advanced organic coronary artery stenosis > 0% of the
luminal diameter . The levels of fibrinopeptide A in these
three subjects were elevated above the normal range before
hyperventilation (5 .7, 4.8 and 3 .7 ng/ml, respectively) .
Plasma levels of beta-thromboglobulin (Fig . 3 and 4; Table
2). Beta-thromboglobulin levels did not change significantly
after hyperventilation in either the patients with coronary
vasospastic angina or the control subjects (from 30 .8 ± 3 .8 to
33 .7 ± 4.3 IU/ml in the patients and from 1  .3 ± 3 .0 to 16 .0
1 .  IU/ml in the control subjects) (Fig . 3, Table 2) . Plasma
levels of platelet factor 4 also did not change significantly in
either the patients or the control subjects (from 3 .1 ± 0 .5 to
3 .5 ± 0.5 IU/ml and from 2 .1 ± 0.4 to 1 .  ± 0.3 IU/ml,
respectively) (Fig . 4) . Arterial blood pH increased and pco,
Figure 3 . Plasma levels of beta-thromboglobulin (BTG) before and
after hyperventilation in the 12 control subjects (left panel) and I I
patients with coronary vasospastic angina (CSA) (right panel) .
There was no significant change in either group .
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Figure 4 . Plasma levels of platelet factor 4 (PF4) before and after
hyperventilation in the 12 control subjects (left panel) and 11 patients
with coronary vasospastic angina (CSA) (right panel) . There was no
significant change in either group .
decreased significantly after hyperventilation in both groups
but there were no significant intergroup differences in these
values (Table 2) .
Discussion
Plasma fibrinopeptide A levels in acute ischemia . The
pathophysiology of acute myocardial infarction has been a
subject of considerable discussion (23,24) . The respective
roles of coronary thrombosis and coronary artery spasm in
the pathogenesis of acute myocardial infarction are still
unclear . Several investigators (11-14) have reported that
coronary spasm may be responsible for acute myocardial
infarction in some patients ; however, direct cause and effect
have not been shown in most of the reported cases . In this
study, plasma fibrinopeptide A levels increased significantly
during the anginal attack induced by hyperventilation in the
patients with coronary vasospastic angina, but did not
change significantly in the control subjects, in whom no
attack was induced after hyperventilation .
Fibrinopeptide A is a small peptide released from fibrin-
ogen by the specific action of thrombin . Normal blood levels
are low and become elevated during thrombotic and pre-
thrombotic states (21) . Several investigators (6-10,21) have
reported the elevation of plasma fibrinopeptide A levels in
patients with various forms of ischemic heart disease, in-
cluding acute myocardial infarction, previous myocardial
infarction, unstable angina and effort angina . However,
plasma fibrinopeptide A levels in patients with coronary
vasospastic angina have not been reported previously .
Plasma beta-thromboglobulin and platelet factor 4 levels in
acute ischemia. These are two platelet-specific proteins that
are secreted from the alpha-granules in platelets during the
Control Subjects (n = 12) Patients With CSA (n = 12)
Before HV After HV
After
Angina
Before HV Attack
FPA (ng/ml) 2.4±0
.5 NS 2 .3±0 .5
2,0±0 .4
t
10
.0±2.4
BTG (IU/ml) 1  .3 ± 3.0 NS 16.0 ± 1 .  30.8 ± 3.8 NS 33 .7 ± 4 .3
PF4 (IU/ml) 2 .1 ± 0.4 NS 1 .  ± 0 .3 3 .1 ± 0.5 NS 3 .5 ± 0.5
Arterial
pH ± 0 .03 7 .3 ±0.01 * 7 .61 ±0.017.3 ±0 .01 7 .5 
Pco, (mm Hg) 42.0±.  * 23 .4 ± 1 .7 41 .5 ± 1 .0 * 21 .6 ± 1 .0
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release reaction; they are specific indicators of platelet
activation in vivo (25) . As opposed to plasma fibrinopeptide
A levels, plasma beta-thromboglobulin and platelet factor 4
levels did not increase during the attack in the patients with
coronary vasospastic angina . There are reports (26,27)
showing an elevation of beta-thromboglobulin or platelet
factor 4 in patients with stable angina, unstable angina and
acute myocardial infarction . However, Theroux et al . (10)
recently found no significant differences in beta-thromboglo-
bulin, platelet factor 4, thromboxane B, and platelet aggre-
gation between patients with unstable angina and those with
stable angina . Jaffe et al . (28) also showed normal values for
plasma beta-thromboglobulin and platelet factor 4 even
during the acute phase of myocardial infarction . Although
the discrepancy we observed between the levels of fibrin-
opeptide A and those of beta-thromboglobulin and platelet
factor 4 during the anginal attack in our patient group cannot
be readily explained, our results indicate that fibrinopeptide
A is a more sensitive index for detecting directional changes
in hemostatic activation than is beta-thromboglobulin or
platelet factor 4 .
The presence of a high concentration of fibrinopeptide A
during the attack in the patients with coronary vasospastic
angina indicates that coronary spasm may induce thrombin
generation in the coronary artery . Thus, our study suggests
that coronary artery spasm may trigger the thrombotic
process in the coronary artery and may lead to thrombus
formation and ultimately to acute myocardial infarction in
some patients .
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